Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Inclusion criteria

• ✓. Histologically confirmed newly diagnosed (stage IIIC or IV) or recurrent (any stage) uterine papillary serous carcinoma. Patients with recurrent disease may not have been treated with taxanes in the past.
• ✓. Patients may not receive concurrent radiotherapy while participating in this protocol.
• ✓. Patients may have measurable or non-measurable disease.
• ✓. Patients may have mixed endometrioid or clear cell components in addition to the serous histology.
• ✓. Patients' tumor tissue must express one or more of the following biomarkers: c-Kit, PDGFR-B, or Abl. Positivity will be defined as 2+/3+ intensity in at least 10% of the tumor.
• ✓. Patients must have pretreatment granulocyte count (i.e. segmented neutrophils and bands) of \>/= 1,500/Fl, a hemoglobin level of \>/= 9.0 gm/dl, and a platelet count of \>/= 100,000/Fl.
• ✓. Patients must have an adequate renal function as documented by serum creatinine of \</=2.0 mg/dl.
• ✓. Patients must have adequate hepatic function as documented by a serum bilirubin \</=1.5mg/dl, regardless of whether patients have liver involvement secondary to tumor. Alanine aminotransferase (SGPT) and aspartate aminotransferase (SGOT) must be \</=2.5x institutional upper limit of normal unless the liver is involved with tumor, in which case levels must be \</=5x institutional upper limit of normal.

Exclusion criteria